{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:47:12Z","timestamp":1784634432796,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary Sj\u00f6gren\u2019s syndrome (pSS) is an autoimmune inflammatory disease with profound clinical heterogeneity, where excessive activation of the type I interferon (IFN) system is considered one of the key mechanisms in disease pathogenesis. Here we present a DNA methylation-based IFN system activation score (DNAm IFN score) and investigate its potential associations with sub-phenotypes of pSS. The study comprised 100 Swedish patients with pSS and 587 Swedish controls. For replication, 48 patients with pSS from Stavanger, Norway, were included. IFN scores were calculated from DNA methylation levels at the IFN-induced genes RSAD2, IFIT1 and IFI44L. A high DNAm IFN score, defined as &amp;gt; mean<jats:sub>controls<\/jats:sub> +2SD<jats:sub>controls<\/jats:sub> (IFN score &amp;gt;4.4), was observed in 59% of pSS patients and in 4% of controls (p=1.3x10<jats:sup>-35<\/jats:sup>). Patients with a high DNAm IFN score were on average seven years younger at symptom onset (p=0.017) and at diagnosis (p=3x10<jats:sup>-3<\/jats:sup>). The DNAm IFN score levels were significantly higher in pSS positive for both SSA and SSB antibodies compared to SSA\/SSB negative patients (p<jats:sub>discovery<\/jats:sub>=1.9x10<jats:sup>-8<\/jats:sup>, p<jats:sub>replication<\/jats:sub>=7.8x10<jats:sup>-4<\/jats:sup>). In patients positive for both SSA subtypes Ro52 and Ro60, an increased score was identified compared to single positive patients (p=0.022). Analyzing the discovery and replication cohorts together, elevated DNAm IFN scores were observed in pSS with hypergammaglobulinemia (p=2x10<jats:sup>-8<\/jats:sup>) and low C4 (p=1.5x10<jats:sup>-3<\/jats:sup>) compared to patients without these manifestations. Patients &amp;lt; 70 years with ongoing lymphoma at DNA sampling or lymphoma at follow-up (n=7), presented an increased DNAm IFN score compared to pSS without lymphoma (p=0.025). In conclusion, the DNAm-based IFN score is a promising alternative to mRNA-based scores for identification of patients with activation of the IFN system and may be applied for patient stratification guiding treatment decisions, monitoring and inclusion in clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2021.702037","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:50:26Z","timestamp":1626436226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["DNA Methylation-Based Interferon Scores Associate With Sub-Phenotypes in Primary Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Juliana","family":"Imgenberg-Kreuz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna K.","family":"Sandling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine Br\u00e6kke","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein Joar Augl\u00e6nd","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"Omdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christine","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"R\u00f6nnblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija-Leena","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnel","family":"Nordmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa367","article-title":"Genetic and Clinical Basis for Two Distinct Subtypes of Primary Sjogren\u2019s Syndrome","volume":"60","author":"Thorlacius","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren\u2019s Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and Other Malignancies in Primary Sjogren\u2019s Syndrome: A Cohort Study on Cancer Incidence and Lymphoma Predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.20998","article-title":"Activation of the Type I Interferon System in Primary Sjogren\u2019s Syndrome: A Possible Etiopathogenic Mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1519396","article-title":"Interferon Activation in Primary Sjogren\u2019s Syndrome: Recent Insights and Future Perspective as Novel Treatment Target","volume":"14","author":"Bodewes","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/138920112802273290","article-title":"Primary Sjogren\u2019s Syndrome and the Type I Interferon System","volume":"13","author":"Nordmark","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I Interferons (Alpha\/Beta) in Immunity and Autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20798","article-title":"Coordinate Overexpression of Interferon-Alpha-Induced Genes in Systemic Lupus Erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of Interferon Type I Signature in CD14 Monocytes of Patients With Sjogren\u2019s Syndrome and Association With Disease Activity and BAFF Gene Expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic Interferon Type I and Type II Signatures in Primary Sjogren\u2019s Syndrome Reveal Differences in Biological Disease Activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II Interferon Signatures in Sjogren\u2019s Syndrome Pathogenesis: Contributions in Distinct Clinical Phenotypes and Sjogren\u2019s Related Lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202552","article-title":"Mxa as a Clinically Applicable Biomarker for Identifying Systemic Interferon Type I in Primary Sjogren\u2019s Syndrome","volume":"73","author":"Maria","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000995","article-title":"Protein and DNA Methylation-Based Scores as Surrogate Markers for Interferon System Activation in Patients With Primary Sjogren\u2019s Syndrome","volume":"6","author":"Bjork","year":"2020","journal-title":"RMD Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv095","article-title":"IFN-Alpha Production by Plasmacytoid Dendritic Cell Associations With Polymorphisms in Gene Loci Related to Autoimmune and Inflammatory Diseases","volume":"24","author":"Berggren","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202500","article-title":"Genetic Associations to Germinal Centre Formation in Primary Sjogren\u2019s Syndrome","volume":"73","author":"Reksten","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208659","article-title":"Genome-Wide DNA Methylation Analysis in Multiple Tissues in Primary Sjogren\u2019s Syndrome Reveals Regulatory Effects at Interferon-Induced Genes","volume":"75","author":"Imgenberg-Kreuz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212379","article-title":"DNA Methylation Mapping Identifies Gene Regulatory Effects in Patients With Systemic Lupus Erythematosus","volume":"77","author":"Imgenberg-Kreuz","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu049","article-title":"Minfi: A Flexible and Comprehensive Bioconductor Package for the Analysis of Infinium DNA Methylation Microarrays","volume":"30","author":"Aryee","year":"2014","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2105-13-86","article-title":"DNA Methylation Arrays as Surrogate Measures of Cell Mixture Distribution","volume":"13","author":"Houseman","year":"2012","journal-title":"BMC Bioinf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e41361","DOI":"10.1371\/journal.pone.0041361","article-title":"Differential DNA Methylation in Purified Human Blood Cells: Implications for Cell Lineage and Studies on Disease Susceptibility","volume":"7","author":"Reinius","year":"2012","journal-title":"PLoS One"},{"key":"B21","article-title":"How Immunological Profile Drives Clinical Phenotype of Primary Sjogren\u2019s Syndrome at Diagnosis: Analysis of 10,500 Patients (Sjogren Big Data Project)","author":"Brito-Zeron","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin\u2019s Lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24597","article-title":"Antibodies to Both Ro52 and Ro60 may Identify Sjogren\u2019s Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies","author":"Armagan","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral Blood Gene Expression Profiling in Sjogren\u2019s Syndrome","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.34599","article-title":"B Lymphocytes Enhance Interferon-Alpha Production by Plasmacytoid Dendritic Cells","volume":"64","author":"Berggren","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0183946","DOI":"10.1371\/journal.pone.0183946","article-title":"Plasmacytoid Dendritic Cells and RNA-Containing Immune Complexes Drive Expansion of Peripheral B Cell Subsets With an SLE-Like Phenotype","volume":"12","author":"Berggren","year":"2017","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation Through Type I Interferon and Interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1038\/s41598-017-06516-1","article-title":"Novel Risk Genes for Systemic Lupus Erythematosus Predicted by Random Forest Classification","volume":"7","author":"Almlof","year":"2017","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1191\/096120300674499064","article-title":"Activation of Type I Interferon System in Systemic Lupus Erythematosus Correlates With Disease Activity But Not With Antiretroviral Antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"key":"B30","doi-asserted-by":"publisher","first-page":"key360","DOI":"10.1093\/rheumatology\/key360","article-title":"Innate Immunity and Interferons in the Pathogenesis of Sjogren\u2019s Syndrome","volume":"15","author":"Bodewes","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of Type I Interferons in the Activation of Autoreactive B Cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lab.2006.01.001","article-title":"Characterization of Peripheral Natural Killer Cells in Primary Sjogren\u2019s Syndrome: Impaired NK Cell Activity and Low NK Cell Number","volume":"147","author":"Izumi","year":"2006","journal-title":"J Lab Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7523914","DOI":"10.1155\/2020\/7523914","article-title":"The Increased Ratio of Blood CD56(Bright) NK to CD56(dim) Nk Is a Distinguishing Feature of Primary Sjogren\u2019s Syndrome","volume":"2020","author":"Ming","year":"2020","journal-title":"J Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619","article-title":"Eular Sjogren\u2019s Syndrome Disease Activity Index: Development of a Consensus Systemic Disease Activity Index for Primary Sjogren\u2019s Syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13293-017-0137-7","article-title":"Difference in Clinical Presentation Between Women and Men in Incident Primary Sjogren\u2019s Syndrome","volume":"8","author":"Ramirez Sepulveda","year":"2017","journal-title":"Biol Sex Differ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13293-017-0146-6","article-title":"Long-Term Follow-Up in Primary Sjogren\u2019s Syndrome Reveals Differences in Clinical Presentation Between Female and Male Patients","volume":"8","author":"Ramirez Sepulveda","year":"2017","journal-title":"Biol Sex Differ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez242","article-title":"Hydroxychloroquine Treatment Downregulates Systemic Interferon Activation in Primary Sjogren\u2019s Syndrome in the JOQUER Randomized Trial","volume":"59","author":"Bodewes","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210509","article-title":"H1N1 Vaccination in Sjogren\u2019s Syndrome Triggers Polyclonal B Cell Activation and Promotes Autoantibody Production","volume":"76","author":"Brauner","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of Rituximab in Systemic Manifestations of Primary Sjogren\u2019s Syndrome: Results in 78 Patients of the AutoImmune and Rituximab Registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and Safety of Belimumab in Primary Sjogren\u2019s Syndrome: Results of the BELISS Open-Label Phase II Study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjogren Syndrome: The JOQUER Randomized Clinical Trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/biom11020251","article-title":"The Role of Interferons in the Pathogenesis of Sjogren\u2019s Syndrome and Future Therapeutic Perspectives","volume":"11","author":"Del Papa","year":"2021","journal-title":"Biomolecules"},{"key":"B43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13075-018-1702-0","article-title":"Cytokine Production by Activated Plasmacytoid Dendritic Cells and Natural Killer Cells is Suppressed by an IRAK4 Inhibitor","volume":"20","author":"Hjorton","year":"2018","journal-title":"Arthritis Res Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.702037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:50:29Z","timestamp":1626436229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.702037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2021.702037"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.702037","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"article-number":"702037"}}